GI Dynamics has announced that the new data on its novel non-invasive device to treat obesity and type 2 diabetes, EndoBarrier™, currently in the clinical trial phase, will be presented soon. The EndoBarrier Gastrointestinal Liner will be a new sign of hope for the 99% of patients qualified as clinically obese and do not want to go for bariatric surgery. The data will be put forward at the International Federation for Surgery of Obesity and Metabolic Disorders (IFSO) 13th World Congress in Buenos Aires, Argentina.

The New York-Presbyterian Hospital/Weill Cornell Medical Center is enrolling patients for the research study of an investigational implantable device for the treatment of type-2 diabetes patients who are overweight and do not respond to the prevalent anti-diabetic treatments. The device is placed in the body through a minimally invasive laparoscopic process. The process can be conducted in outpatient settings.